Lim T, Por C, Beh Y, Schee J, Tan A
Clin Park Relat Disord. 2023; 9:100218.
PMID: 37808566
PMC: 10556813.
DOI: 10.1016/j.prdoa.2023.100218.
Singh R, Pandey S
Ann Indian Acad Neurol. 2022; 25(5):821-831.
PMID: 36561038
PMC: 9764914.
DOI: 10.4103/aian.aian_64_22.
van der Veen S, Caviness J, Dreissen Y, Ganos C, Ibrahim A, Koelman J
Clin Neurophysiol Pract. 2022; 7:285-316.
PMID: 36324989
PMC: 9619152.
DOI: 10.1016/j.cnp.2022.09.003.
Pena A, Caviness J
Neurotherapeutics. 2020; 17(4):1665-1680.
PMID: 32910414
PMC: 7851206.
DOI: 10.1007/s13311-020-00922-6.
Christodoulides I, Giamouriadis A, Bashford J, Barkas K
BMJ Case Rep. 2018; 2018.
PMID: 30061134
PMC: 6069946.
DOI: 10.1136/bcr-2018-225455.
Treatment of Propriospinal Myoclonus at Sleep Onset.
Byun J, Lee D, Rhee H, Shin W
J Clin Neurol. 2017; 13(3):293-295.
PMID: 28516739
PMC: 5532327.
DOI: 10.3988/jcn.2017.13.3.293.
Myoclonus: Pathophysiology and Treatment Options.
Levy A, Chen R
Curr Treat Options Neurol. 2016; 18(5):21.
PMID: 27039330
DOI: 10.1007/s11940-016-0404-7.
Spinal-generated movement disorders: a clinical review.
Termsarasab P, Thammongkolchai T, Frucht S
J Clin Mov Disord. 2016; 2:18.
PMID: 26788354
PMC: 4711055.
DOI: 10.1186/s40734-015-0028-1.
Familial segmental spinal myoclonus: a rare clinical feature of Friedreich's ataxia.
Jain R, Kumar S, Tejwani S
Springerplus. 2015; 4:330.
PMID: 26180750
PMC: 4495095.
DOI: 10.1186/s40064-015-1121-5.
Spinal segmental myoclonus as an unusual presentation of multiple sclerosis.
Alroughani R, Farouk Ahmed S, Khan R, Al-Hashel J
BMC Neurol. 2015; 15:15.
PMID: 25879483
PMC: 4347575.
DOI: 10.1186/s12883-015-0271-y.
An update and review of the treatment of myoclonus.
Mills K, Mari Z
Curr Neurol Neurosci Rep. 2014; 15(1):512.
PMID: 25398378
DOI: 10.1007/s11910-014-0512-2.
Treatment of myoclonus.
Caviness J
Neurotherapeutics. 2013; 11(1):188-200.
PMID: 24037428
PMC: 3899494.
DOI: 10.1007/s13311-013-0216-3.
An unusual presentation of diabetic amyotrophy: myoclonus.
Zaidi S, Chhetri S, Lekwuwa G, Majeed T
BMJ Case Rep. 2013; 2013.
PMID: 23386493
PMC: 3604390.
DOI: 10.1136/bcr-2012-008245.
Use of antiepileptic drugs for hyperkinetic movement disorders.
Siniscalchi A, Gallelli L, De Sarro G
Curr Neuropharmacol. 2011; 8(4):359-66.
PMID: 21629443
PMC: 3080592.
DOI: 10.2174/157015910793358187.
Myoclonic disorders: a practical approach for diagnosis and treatment.
Kojovic M, Cordivari C, Bhatia K
Ther Adv Neurol Disord. 2011; 4(1):47-62.
PMID: 21339907
PMC: 3036960.
DOI: 10.1177/1756285610395653.
Levetiracetam reduces myoclonus in corticobasal degeneration: report of two cases.
Kovacs T, Farsang M, Vitaszil E, Barsi P, Gyorke T, Szirmai I
J Neural Transm (Vienna). 2009; 116(12):1631-4.
PMID: 19756367
DOI: 10.1007/s00702-009-0301-2.
Levetiracetam in the treatment of epilepsy.
Abou-Khalil B
Neuropsychiatr Dis Treat. 2008; 4(3):507-23.
PMID: 18830435
PMC: 2526377.
DOI: 10.2147/ndt.s2937.
Benefit-risk assessment of levetiracetam in the treatment of partial seizures.
Abou-Khalil B
Drug Saf. 2005; 28(10):871-90.
PMID: 16180937
DOI: 10.2165/00002018-200528100-00004.
Myoclonus.
Nirenberg M, Frucht S
Curr Treat Options Neurol. 2005; 7(3):221-230.
PMID: 15814075
DOI: 10.1007/s11940-005-0015-1.
Similarities in Mechanisms and Treatments for Epileptic and Nonepileptic Myoclonus.
Krauss G, Mathews G
Epilepsy Curr. 2004; 3(1):19-21.
PMID: 15309099
PMC: 321155.
DOI: 10.1111/j.1535-7597.2003.03107.x.
